- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01240447
Immunotherapy With Racotumomab Versus Support Treatment in Advanced Non-small Cell Lung Cancer Patients
A Prospective, Randomised, Open Label Phase II Study of Active Specific Immunotherapy With Racotumomab Versus Support Treatment in Patients With Advanced Non-small Cell Lung Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Buenos Aires, Argentina, C1417DTB
- Instituto de Oncología "Angel H. Roffo"
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The patient (aged over 21 years, either sex) can comply with the protocol and scheduled appointments and sign voluntarily the informed consent form
- Diagnosis of Non-small cell lung cancer (NSCLC) stages IIIA (surgically unresectable), IIIB or IV, according to the TNM classification (Tumor-Nodes-Metastases) version 6a, confirmed by cytology or histology, if possible available for determination of ganglioside expression
Patients may enter the study if they have accomplished an objective response (complete response or partial response) or disease stabilisation (by Response Evaluation Criteria In Solid Tumours [RECIST]) after completion of standard onco-specific treatment. In all cases, response should be documented.
For stage IIIA and IIIB without pleural effusion ("dry IIIB") standard treatment is considered as follows: 2 - 4 cycles of platinum-based chemotherapy and/or radiotherapy with curative intent in accordance with National Comprehensive Cancer Network (NCCN) guidelines For stage IIIB with pleural effusion ("wet IIIB") and stage IV standard treatment is considered as follows: 4 - 6 cycles of chemotherapy based on platinum. In case of pleural or pericardial effusion requiring local treatment, it will be provided prior to study entry.
- Patients with an interval greater than 30 and not more than 90 days between the completion of oncospecific treatment and study entry. Completion of treatment is defined as the last day of administration of chemotherapy or the last day of radiotherapy. Patients should have recovered from any related episode of acute toxicity of degree greater than 1 (except alopecia). Patients who have received a monoclonal antibody (eg bevacizumab) should also have discontinued its use for at least 30 days before inclusion.
- The subject is male or female, aged greater than or equal to 21 years
- Performance status (Eastern Cooperative Oncology Group [ECOG]) less than or equal to 1
Acceptable organ functionality as defined by the following parameters:
- Electrocardiogram (ECG) without significant abnormalities, performed within 14 days prior to admission
- Haemoglobin greater than or equal to 90 g/L
- Total leukocyte count greater than or equal to 3.0 x 10^9/L
- Absolute neutrophil count greater than or equal to 1.5 x 10^9/L
- Total bilirubin less than or equal to 1.5 times upper limit of normal or twice the limit normal than in case liver metastases are present
- Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than or equal to 2.5 times upper limit of normal (less than or equal to five times the normal maximum in case liver metastases are present)
- Creatinine less than or equal to 2 mg/dL
- Life expectancy of at least four months
Exclusion Criteria:
- Patient is pregnant or breastfeeding
- Has received chemotherapy, radiotherapy, immunotherapy or surgery within 30 days prior to inclusion
- Hypersensitivity to any component of the formulation
- Patients of childbearing potential of either sex who are not using an adequate method of contraception during treatment to avoid pregnancy (own or of partner). For females: intrauterine devices, hormonal contraceptives, barrier methods or sterilisation. For males: vasectomy or condoms with spermicide.
- Patients receiving or having received other investigational drugs 30 days prior to study entry
- History of autoimmune diseases
- Decompensated chronic diseases
- Acute allergic disorders or history of severe allergic reactions
- Known brain metastases uncontrolled with surgery and/or radiation therapy or under current corticosteroid therapy
- History of inflammatory or demyelinating disease of the central or peripheral nervous system
- Uncontrolled intercurrent illnesses, including active infection, symptomatic congestive heart failure, unstable angina or cardiac arrhythmia and psychiatric diseases implying patient incompetence
- Other malignancies, with the exception of basal cell carcinoma, in situ cervical carcinoma, incidental prostate cancer (T1a, Gleason less than or equal to 6, prostate specific antigen [PSA] less than 0.5 ng/ml), tumour or any other tumour adequately treated and with a disease-free period greater than or equal to 5 years
- Chronic treatment with systemic corticosteroids at doses greater than 0.5 mg/kg/day or a maximum of 40 mg/day of prednisone or equivalent
- The subject has a history of drug abuse (illicit drugs) or alcohol abuse (defined as regular or periodic ingestion of more than four drinks a day) in the last 2 years
- Positive serology for hepatitis B, C or known human immunodeficiency virus (HIV) infection
- Uncontrolled hypercalcaemia greater than or equal to 2.9 mmol/L (or grade greater than 1 according to the Common Terminology Criteria for Adverse Events [CTCAE] version 3.0)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
OTHER: Best support treatment
|
Patients will receive best support treatment as indicated by the investigator.
In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
|
EXPERIMENTAL: Racotumomab vaccine
|
Patients will receive best support treatment and vaccination with racotumomab.
The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met.
If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel.
Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Adverse events as a measure of safety and tolerability
Time Frame: Until death, on average during 17 months
|
Safety will be evaluated at each study visit according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and will include physical examination with vital signs, performance status as per the Eastern Cooperative Oncology Group scale(ECOG scale), laboratory tests and clinical history.
|
Until death, on average during 17 months
|
Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside
Time Frame: Baseline
|
Baseline
|
|
Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.
Time Frame: Baseline
|
Baseline
|
|
Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.
Time Frame: Baseline
|
Baseline
|
|
Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)
Time Frame: Baseline
|
Baseline
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines
Time Frame: Baseline
|
Baseline
|
|
Evaluation of the reactivity if the antibodies against X63 tumor line
Time Frame: Baseline
|
Baseline
|
|
Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.
Time Frame: Month 2
|
Month 2
|
|
Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.
Time Frame: Month 4
|
Month 4
|
|
Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.
Time Frame: Month 8
|
Month 8
|
|
Determination of T supressor cell (Treg cell) frequency by immunostaining and flow cytometry.
Time Frame: Month 12
|
Month 12
|
|
Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)
Time Frame: Month 2
|
Month 2
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines.
Time Frame: Baseline
|
Baseline
|
|
Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside
Time Frame: Month 2
|
Month 2
|
|
Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside
Time Frame: Month 8
|
Month 8
|
|
Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside
Time Frame: Month 4
|
Month 4
|
|
Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside
Time Frame: Month 12
|
Month 12
|
|
Determination of IgM and IgG antibody titers against N-Glycolil-GM3 ganglioside
Time Frame: Every 4 months (after the first year, on average during 17 months)
|
Every 4 months (after the first year, on average during 17 months)
|
|
Evaluation of the reactivity if the antibodies against X63 tumor line
Time Frame: Month 2
|
Month 2
|
|
Evaluation of the reactivity if the antibodies against X63 tumor line
Time Frame: Month 12
|
Month 12
|
|
Evaluation of the reactivity if the antibodies against X63 tumor line
Time Frame: Every 4 months (after the first year, on average during 17 months)
|
Every 4 months (after the first year, on average during 17 months)
|
|
Evaluation of the reactivity if the antibodies against X63 tumor line
Time Frame: Month 4
|
Month 4
|
|
Evaluation of the reactivity if the antibodies against X63 tumor line
Time Frame: Month 8
|
Month 8
|
|
Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)
Time Frame: Month 4
|
Month 4
|
|
Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)
Time Frame: Month 8
|
Month 8
|
|
Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)
Time Frame: Month 12
|
Month 12
|
|
Evaluation of the reactivity of the antibodies against the patients tumoral tissue (whenever samples are available)
Time Frame: Every 4 months (after the first year, on average during 17 months)
|
Every 4 months (after the first year, on average during 17 months)
|
|
Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.
Time Frame: Month 2
|
Month 2
|
|
Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.
Time Frame: Month 4
|
Month 4
|
|
Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.
Time Frame: Month 8
|
Month 8
|
|
Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.
Time Frame: Month 12
|
Month 12
|
|
Determination of gamma interferon by ELISPOT (enzyme-linked immunosorbent spot) assay.
Time Frame: Every 4 months (after the first year, on average during 17 months)
|
Every 4 months (after the first year, on average during 17 months)
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines
Time Frame: Month 2
|
Month 2
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines
Time Frame: Month 4
|
Month 4
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines
Time Frame: Month 8
|
Month 8
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines
Time Frame: Month 12
|
Month 12
|
|
Measurement of pro-inflammatory and anti-inflammatory cytokines
Time Frame: Every 4 months (after the first year, on average during 17 months)
|
Every 4 months (after the first year, on average during 17 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Survival
Time Frame: Until date of death or last censored observation
|
On average, during 17 months
|
Until date of death or last censored observation
|
Progression free survival
Time Frame: Until first progression of disease
|
Tumour evaluations will be performed every 2 months and evaluated as per Response Evaluation Criteria in Solid Tumors (RECIST).
|
Until first progression of disease
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Gabriela Cinat, MD, Instituto de Oncología "Angel H. Roffo"
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AR-RACO-02-08
- ISRCTN47153584 (REGISTRY: Intl Standard Randomised Controlled Trial Number Register)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Non-small Cell Lung Cancer
-
Mythic TherapeuticsRecruitingNon-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung CancerUnited States, Australia, Korea, Republic of, United Kingdom
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerFrance, Korea, Republic of, United Kingdom, Spain
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerBelgium, United States, Korea, Republic of, Taiwan, United Kingdom, Netherlands
-
AstraZenecaCompletedAdvanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung CancerUnited States, France, Germany, Korea, Republic of, Taiwan, United Kingdom, Spain, Italy, Japan, Australia
-
Peking University First HospitalMerck Sharp & Dohme LLCNot yet recruitingAdvanced Non-squamous Non-small-cell Lung Cancer | Metastatic Non-squamous Non Small Cell Lung Cancer | Recurrent Non-Squamous Non-Small Cell Lung CancerChina
-
Gradalis, Inc.WithdrawnLung Neoplasms | Advanced Non-small Cell Lung Cancer | Metastatic Non-small Cell Lung CancerUnited States
-
LianBio LLCRecruitingAdvanced Solid Tumor | Advanced or Metastatic Non-small Cell Lung CancerChina
-
Gilead SciencesArcus Biosciences, Inc.RecruitingLung Cancer | Advanced or Metastatic Non-Small-Cell Lung Cancer | Resectable Non-Small-Cell Lung CancerUnited States, Korea, Republic of, Taiwan, Hong Kong, Israel, United Kingdom
-
Cancer Research UKBicycle TherapeuticsCompletedNon-Small Cell Lung Cancer | Advanced Solid Tumours | Oesophageal Cancer | Non-Small Cell Lung SarcomaUnited Kingdom
-
Mirati Therapeutics Inc.RecruitingAdvanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Clinical Trials on Best support treatment
-
Recombio SLEurofarma Laboratorios S.A.; Laboratorio Elea Phoenix S.A.; Innogene Kalbiotech... and other collaboratorsUnknownNSCLC | Lung Cancer, Non-small CellBrazil, Indonesia, Argentina, Cuba, Philippines, Singapore, Thailand
-
Institut für Klinisch-Kardiovaskuläre Forschung...Technical University of MunichUnknownIntermittent Claudication | Complex Lesions of the Superficial Femoral ArteryGermany, Austria
-
University of North Carolina, Chapel HillNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingDiabetes Mellitus, Type 2United States
-
Biotronik AGCompletedRenal Artery StenosisGermany
-
Insel Gruppe AG, University Hospital BernActive, not recruitingCerebral HemorrhageBelgium, France, Germany, Finland, Austria, Netherlands, Spain, Switzerland
-
University of UtahRecruitingAnemia | Thrombocytopenia | Coagulopathy, Mild | HypofibrinogenemiaUnited States
-
Brigham and Women's HospitalBayerRecruitingChronic Kidney Diseases | Type2DiabetesUnited States
-
University Hospital, MontpellierNot yet recruiting
-
Yonsei UniversityTerminatedAcute Ischemic StrokeKorea, Republic of
-
Rennes University HospitalActive, not recruitingTricuspid RegurgitationFrance, Belgium